PMID- 29658083
OWN - NLM
STAT- MEDLINE
DCOM- 20180919
LR  - 20180919
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 164
IP  - 6
DP  - 2018 Apr
TI  - Antidiabetic Properties of Low-Molecular-Weight BDNF Mimetics Depend on the Type 
      of Activation of Post-Receptor Signaling Pathways.
PG  - 734-737
LID - 10.1007/s10517-018-4069-y [doi]
AB  - Reduced proliferation and enhanced apoptosis of beta cells in diabetes mellitus are 
      associated with a deficiency of brain-derived neurotrophic factor (BDNF). 
      Low-molecular weight compounds similar to different BDNF loops were synthesized 
      at the V. V. Zakusov Research Institute of Pharmacology. They produce a 
      potentiating effect on TrkB phosphorylation, but differently activate 
      post-receptor signaling pathways. We compared their effects on the severity of 
      streptozotocin-induced diabetes mellitus in C57Bl/6 mice. The antidiabetic effect 
      (estimated from the degree of hyperglycemia and dynamics of body weight) was 
      typical of GSB-214 compound that selectively activates PI3K/Akt. This activity 
      was not revealed in GTS-201, selective activator of MAPK/Erk. GSB-106 compound 
      activating both signaling pathways exhibited weak antidiabetic activity. Our 
      results indicate that the antidiabetic effect is mainly related to activation of 
      the PI3K/Akt signaling pathway.
FAU - Ostrovskaya, R U
AU  - Ostrovskaya RU
AD  - V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia. 
      rita.ostrovskaya@gmail.com.
FAU - Yagubova, S S
AU  - Yagubova SS
AD  - V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
FAU - Gudasheva, T A
AU  - Gudasheva TA
AD  - V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
FAU - Seredenin, S B
AU  - Seredenin SB
AD  - V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
LA  - eng
PT  - Journal Article
DEP - 20180416
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Diamines)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Succinates)
RN  - 5W494URQ81 (Streptozocin)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Mapk1 protein, mouse)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Biomimetic Materials/chemical synthesis/pharmacology
MH  - Brain-Derived Neurotrophic Factor/*chemistry
MH  - Diabetes Mellitus, Experimental/chemically induced/*drug 
      therapy/genetics/metabolism
MH  - Diamines/chemical synthesis/*pharmacology
MH  - Enzyme Activation
MH  - Gene Expression Regulation
MH  - Hypoglycemic Agents/chemical synthesis/*pharmacology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mitogen-Activated Protein Kinase 1/genetics/metabolism
MH  - Mitogen-Activated Protein Kinase 3/genetics/metabolism
MH  - Mitogen-Activated Protein Kinases/genetics/metabolism
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - Proto-Oncogene Proteins c-akt/agonists/genetics/metabolism
MH  - Signal Transduction/*drug effects
MH  - Streptozocin
MH  - Succinates/chemical synthesis/*pharmacology
OTO - NOTNLM
OT  - C57Bl/6 mice
OT  - diabetes
OT  - low-molecular-weight BDNF mimetics
OT  - streptozotocin
EDAT- 2018/04/17 06:00
MHDA- 2018/09/20 06:00
CRDT- 2018/04/17 06:00
PHST- 2017/07/12 00:00 [received]
PHST- 2018/04/17 06:00 [pubmed]
PHST- 2018/09/20 06:00 [medline]
PHST- 2018/04/17 06:00 [entrez]
AID - 10.1007/s10517-018-4069-y [pii]
AID - 10.1007/s10517-018-4069-y [doi]
PST - ppublish
SO  - Bull Exp Biol Med. 2018 Apr;164(6):734-737. doi: 10.1007/s10517-018-4069-y. Epub 
      2018 Apr 16.